Dr. Nicholas Jones, partner and patent attorney at Withers & Rogers, discusses what the pharma industry can learn from its experiences of working collaboratively during the COVID-19 pandemic by establishing best practice and minimising risks.
A new report sets out 20 key recommendations which, upon implementation, would set the UK on a path to become the global leader in cannabinoid innovation.
Sharon Lamb, partner, and David Gibson, senior associate, McDermott Will & Emery analyse the MHRA consultation to change the UK clinical trial regulations.
Brice Ezzouaouy, senior product manager at Beckman Coulter Life Sciences, looks at the journey of the 2017 IVD Regulation and how it affects different aspects of the industry.
Innovative medicines can bring hope to people with rare diseases – let’s get them to patients, says Paul Catchpole director of Value and Access policy, Association of the British Pharmaceutical Industry.
Ashley Fraser and Clara Zacharko, CRA Life Sciences Practice, Toronto look at what revised guidelines to the Patented Medicine Prices Review Board means for drug pricing in Canada.
Dr Ash Ramzan, founder and principal consultant at regulatory affairs consultancy, Woodley BioReg looks at how the key requirements of the Falsified Medicines Directive are being fulfilled by stakeholders and manufacturers.
Christophe Hilbert, senior manager of Access, Value, and Evidence Strategy, Europe at bluebird bio explores the problems of pricing and reimbursement for gene and cell therapies in Europe.
Dr Clive Glover, director, Strategy, Pall Corporation discusses recent industry developments surrounding cell and gene therapies and why safety is a key priority for this treatment area.
At a time of global focus on getting drug and vaccines to market quickly and safely, 2021 looks set to be the year when the potential of IDMP is realised.
